Adlai Nortye Ltd. announced that the first patient was dosed in the United States in early February 2026 in its ongoing global Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor for advanced or metastatic solid tumors harboring RAS mutations. The trial is conducted in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd., with Adlai Nortye retaining ex-China rights.
Key takeaways
First patient dosed in U.S. in early February 2026 in Phase 1 trial of AN9025
AN9025 is an oral pan-RAS (ON) inhibitor for solid tumors with RAS mutations
Trial is first-in-human, multicenter, open-label evaluating safety, tolerability, PK, and anti-tumor activity
Collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm)
Adlai Nortye retains ex-China rights; ASK Pharm holds rights in mainland China, Hong Kong, Macao
Quote from Dr. Archie Tse, Head of R&D, on milestone and strategy